Celldex Therapeutics, Inc.
Celldex Therapeutics (CLDX) is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies, principally for oncology and immune-related diseases. Investors should know the company’s value stems from a pipeline of experimental candidates that must clear multiple clinical and regulatory milestones before potential commercialisation. With a market capitalisation of about $1.85bn, Celldex is a small-cap biotech and typically more volatile than established pharmaceutical firms. Key upside catalysts include positive clinical trial readouts, regulatory approvals and strategic partnerships; key risks include trial failures, regulatory setbacks, competition and the potential need for additional financing. The stock is generally suited to investors who accept high binary risk, long development timelines and no near-term dividend income. This summary is educational only and not personal advice; values can rise and fall and past performance is not a reliable guide to future returns.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Celldex Therapeutics' stock, believing its price could rise to $53.
Financial Health
Celldex Therapeutics is generating modest revenue and cash flow, indicating stable but limited financial strength.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring CLDX
FDA Cancer Warning: Beyond the Treatment Headlines
The FDA's new boxed warning for a major cancer therapy from Johnson & Johnson and Legend Biotech highlights the serious side effects of advanced treatments. This focus creates an investment opportunity in companies that develop drugs and therapies to help manage these adverse reactions, improving patient quality of life.
Published: October 12, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Catalysts
Clinical readouts and regulatory milestones can materially affect value; positive data may drive upside, though trial outcomes are uncertain.
Binary Clinical Risk
Many biotech outcomes are binary — success or failure in trials — which can lead to sharp share price moves and heightened volatility.
Funding & Partnerships
Partnerships or capital raises can accelerate development or dilute shareholders; monitor announcements that affect cash runway and strategic direction.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
